Visser PJ. Role of cognitive testing in disease modifying AD trials. J Nutr Health Aging. 2006;10(2):131–3.
Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer’s and Dementia. 2010;6(6):456–64.
Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA. 2010 Nov 3;304(17):1903.
Cummings J, Ritter A, Zhong K. Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future. Journal of Alzheimer’s Disease. 2018 Jun 12;64(s1):S3–22.
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011 Jul;32(7):1207–18.
Barceló-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n−3 fatty acids: Benefits for human health and a role in maintaining tissue n−3 fatty acid levels. Prog Lipid Res. 2009 Nov;48(6):355–74.
Baker EJ, Miles EA, Burdge GC, Yaqoob P, Calder PC. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog Lipid Res. 2016 Oct;64:30–56.
Metherel AH, Valenzuela R, Klievik BJ, Cisbani G, Rotarescu RD, Gonzalez-Soto M, et al. Dietary docosahexaenoic acid (DHA) downregulates liver DHA synthesis by inhibiting eicosapentaenoic acid elongation. J Lipid Res. 2024 Jun;65(6):100548.
Yassine HN, Croteau E, Rawat V, Hibbeln JR, Rapoport SI, Cunnane SC, et al. DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA. Alzheimers Res Ther. 2017 Dec 23;9(1):23.
Sala-Vila A, Fleming J, Kris-Etherton P, Ros E. Impact of α-Linolenic Acid, the Vegetable ω-3 Fatty Acid, on Cardiovascular Disease and Cognition. Advances in Nutrition. 2022 Sep;13(5):1584–602.